BeyondSpring posts presentation on phase 2 pembrolizumab-plinabulin-docetaxel NSCLC study

BeyondSpring Inc.

BeyondSpring Inc.

BYSI

0.00
  • BeyondSpring published updated Phase 2 results for pembrolizumab, plinabulin, docetaxel in metastatic NSCLC with secondary resistance to prior immune checkpoint inhibitors.
  • Confirmed ORR 18.2%; median PFS 7.0 months; median duration of response 9.3 months; median OS not reached at Feb. 28, 2026 cutoff.
  • Disease control rate 79.5%; 24-month OS rate 58.0%.
  • Grade 3 or higher treatment-related adverse events in 53.2% of patients; key events included hypertension 17% and neutrophil decrease 17%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief on June 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.